here's that word again - imminent, page-16

Hi Sassy, surely it must be interesting to know a little bit more about Fonda's manufacturer, distributor and marketer.

The Company reported revenues of $1.7 billion during the fiscal year, reflecting a year-over-year increase of 6%. Dr. Reddy's reports revenues under two segments - Global Generics and Pharmaceutical Services & Active Ingredients (PSAI). Revenues at the Global Generics segment increased 10% to $1.2 billion. However, PSAI revenues declined 4% to $441 million during the year.

While generics revenues increased 18% in North America, 19% in Russia and other CIS (Commonwealth of Independent States) markets, and 15% in India, they deteriorated 13% in Europe. In the European market, Germany was worst hit with a 25% drop (due to a decline in the Euro currency), partly mitigated by the rest of Europe experiencing a 27% rise.

During the year, Dr. Reddy's launched 135 new generic products, filed 107 new product registrations, and 56 drug master files (DMF) globally. The total number of abbreviated new drug applications (ANDA) awaiting US Food and Drug Administration (FDA) approval were 75 at the end of fiscal 2011. Of the 75 ANDAs, 37 were Para IV filings and 10 are first-to-file.